Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis

Hepatology Research

Volumn 44, Issue 3, 2014, Pages 288-295

  Tada, Toshifumi ^a   Kumada, Takashi ^a   Toyoda, Hidenori ^a   Kiriyama, Seiki ^a   Tanikawa, Makoto ^a   Hisanaga, Yasuhiro ^a   Kanamori, Akira ^a   Kitabatake, Shusuke ^a   Niinomi, Takuro ^a   Ito, Takanori ^a   Hasegawa, Ryohei ^a   Ando, Yusuke ^a   Yamamoto, Kenta ^a   Tanaka, Tatsuya ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Branched chain amino acids; Hepatitis C; Hepatocarcinogenesis; Hepatocellular carcinoma; Propensity score

Indexed keywords

ALPHA FETOPROTEIN; BRANCHED CHAIN AMINO ACID;

ADULT; AGED; ARTICLE; BODY MASS; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; PROPENSITY SCORE; TREATMENT DURATION; VERY ELDERLY;

EID: 84895153360     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12120     Document Type: Article

References (47)

1. Yamato M, Muto Y, Yoshida T, Kato M, Moriwaki H. Clearance rate of plasma branched-chain amino acids correlates significantly with blood ammonia level in patients with liver cirrhosis. Int Hepatol Commun 1995; 3: 91-96.
2. Okuno M, Moriwaki H, Kato M, Muto Y, Kojima S. Changes in the ratio of branched-chain to aromatic amino acids affect the secretion of albumin in cultured rat hepatocytes. Biochem Biophys Res Commun 1995; 214: 1045-1050.
3. Steigmann F, Szanto PB, Poulos A, Lim PE, Dubin A. Significance of serum aminograms in diagnosis and prognosis of liver diseases. J Clin Gastroenterol 1984; 6: 453-460.
4. Nutritional status in cirrhosis. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. J Hepatol 1994; 21: 317-325.
5. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004; 313: 405-409.
6. Marchesini G, Dioguardi FS, Bianchi GP etal. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92-101.
7. Muto Y, Sato S, Watanabe A etal. Long-Term Survival Study Group. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-713.
8. Marchesini G, Bianchi G, Merli M etal. Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-1801.
9. Muto Y, Sato S, Watanabe A etal. for the Long-Term Survival Study (LOTUS) Group. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-214.
10. Nishikawa H, Osaki Y, Iguchi E etal. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013; 47: 359-366.
11. Tsuchiya K, Asahina Y, Izumi N. Long-term oral supplementation with branched-chain amino acids improves survival and decreases recurrences in patients with hepatocellular carcinoma [in Japanese]. Nihon Shoukakibyo Gakkai Zasshi 2008; 105: 808-816.
12. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
13. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-1619.
14. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44: 102-107.
15. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181.
16. Kasahara A, Hayashi N, Mochizuki K etal. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-1402.
17. Ikeda K, Saitoh S, Arase Y etal. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130.
18. Okanoue T, Itoh Y, Minami M etal. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30: 653-659.
19. Lok AS, Everhart JE, Wright EC etal. HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-849.
20. Di Bisceglie AM, Stoddard AM, Dienstag JL etal. HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011; 53: 1100-1108.
21. Bruix J, Poynard T, Colombo M etal. EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140: 1990-1999.
22. Sugiyama K, Yu L, Nagasue N. Direct effect of branched-chain amino acids on the growth and metabolism of cultured human hepatocellular carcinoma cells. Nutr Cancer 1998; 31: 62-68.
23. Murata K, Moriyama M. Isoleucine, an essential amino acid, prevents liver metastases of colon cancer by antiangiogenesis. Cancer Res 2007; 67: 3263-3268.
24. Yoshiji H, Noguchi R, Kitade M etal. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009; 44: 483-491.
25. Shimizu M, Shirakami Y, Iwasa J etal. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res 2009; 15: 3068-3075.
26. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
27. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
28. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. Journal of the American Statistical Association 1984; 79: 516-524.
29. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985; 39: 33-38.
30. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150: 327-333.
31. The Japan Society of Hepatology. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma: clinical practice guidelines for hepatocellular carcinoma. Hepatology Res 2010; 40 (Suppl s1): 6-7.
32. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29 -36.
33. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, 2000.
34. Kondrup J, Müller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol 1997; 27: 239-247.
35. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 1547-1552.
36. Okabayashi T, Nishimori I, Sugimoto T etal. Effects of branched-chain amino acids-enriched nutrient support for patients undergoing liver resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: 1869-1873.
37. Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 2004; 19: 779-788.
38. Iwasa J, Shimizu M, Shiraki M etal. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 2010; 101: 460-467.
39. Yoshiji H, Noguchi R, Kaji K etal. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol 2010; 45: 443-450.
40. Paradis V, Zalinski S, Chelbi E etal. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
41. Kawaguchi T, Yoshida T, Harada M etal. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
42. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
43. Degos F, Christidis C, Ganne-Carrie N etal. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136.
44. Kumada T, Toyoda H, Kiriyama S etal. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol 2011; 46: 536-544.
45. Ohno T, Tanaka Y, Sugauchi F etal. Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis. Hepatol Res 2008; 38: 683-688.
46. Nakamura I, Ochiai K, Imai Y, Moriyasu F, Imawari M. Restoration of innate host defense responses by oral supplementation of branched-chain amino acids in decompensated cirrhotic patients. Hepatol Res 2007; 37: 1062-1067.
47. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J; DGEM (German Society for Nutritional Medicine), Ferenci P, Holm E, Vom Dahl S, Müller MJ, Nolte W; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25: 285-294.